Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bivalirudin vs Heparin in NSTEMI and STEMI in Patients on Modern Antiplatelet Therapy in SWEDEHEART A Multicenter, Prospective, Randomized Controlled Clinical Trial Based on the SWEDEHEART Platform

Trial Profile

Bivalirudin vs Heparin in NSTEMI and STEMI in Patients on Modern Antiplatelet Therapy in SWEDEHEART A Multicenter, Prospective, Randomized Controlled Clinical Trial Based on the SWEDEHEART Platform

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 27 Sep 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bivalirudin (Primary) ; Heparin
  • Indications Myocardial infarction; Stroke; Thrombosis; Venous thromboembolism
  • Focus Adverse reactions
  • Acronyms VALIDATE-SWEDEHEART
  • Most Recent Events

    • 25 Sep 2023 Results of Individual Patient Data Meta-Analysis , from MATRIX, VALIDATE-SWEDEHEART, ISAR-REACT 4, ACUITY and BRIGHT; comparing the outcomes of bivalirudin and heparin in patients with non-ST-segment-elevation myocardial infarction undergoing PCI, published in the Circulation
    • 28 Aug 2023 Results assessing Bivalirudin versus Heparin in ST and non-ST-segment elevation myocardial infarction for the extended follow-up time presented at the ESC Congress 2023 - Annual Congress of the European Society of Cardiology
    • 07 Nov 2022 Results of pooled subgroup analysis (n=15254) assessing efficacy of bivalirudin versus heparin in patients with STEMI undergoing PCI from BRIGHT, EUROMAX, HEAT-PPCI, HORIZONS-AMI, MATRIX, and VALIDATE-SWEDEHEART studies, presented at the American Heart Association Scientific Sessions 2022.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top